VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
0.588
-0.007 (-1.24%)
Mar 9, 2026, 1:56 PM EDT - Market open
VYNE Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 0.57 | 0.5 | 0.42 | 0.48 | 0.93 | Upgrade
|
| Revenue | 0.57 | 0.5 | 0.42 | 0.48 | 0.93 | Upgrade
|
| Revenue Growth (YoY) | 13.77% | 18.16% | -11.11% | -48.77% | -95.56% | Upgrade
|
| Gross Profit | 0.57 | 0.5 | 0.42 | 0.48 | 0.93 | Upgrade
|
| Selling, General & Admin | 11.08 | 13.19 | 13.38 | 16.39 | 20.3 | Upgrade
|
| Research & Development | 19.24 | 30.95 | 16.31 | 18.39 | 19.54 | Upgrade
|
| Operating Expenses | 30.32 | 44.14 | 29.68 | 34.77 | 39.84 | Upgrade
|
| Operating Income | -29.75 | -43.64 | -29.26 | -34.3 | -38.91 | Upgrade
|
| Interest Expense | - | - | - | - | -5.61 | Upgrade
|
| Interest & Investment Income | 1.72 | 3.83 | 1.39 | 0.36 | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | -0.14 | Upgrade
|
| EBT Excluding Unusual Items | -28.03 | -39.8 | -27.87 | -33.93 | -44.66 | Upgrade
|
| Other Unusual Items | 1.3 | - | - | - | - | Upgrade
|
| Pretax Income | -26.73 | -39.8 | -27.87 | -33.93 | -44.66 | Upgrade
|
| Income Tax Expense | 0 | 0 | - | 0.01 | -0.45 | Upgrade
|
| Earnings From Continuing Operations | -26.74 | -39.81 | -27.87 | -33.95 | -44.21 | Upgrade
|
| Earnings From Discontinued Operations | 0.25 | -0.03 | -0.58 | 10.74 | -29.12 | Upgrade
|
| Net Income | -26.48 | -39.83 | -28.45 | -23.21 | -73.33 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | 0.15 | - | - | Upgrade
|
| Net Income to Common | -26.48 | -39.83 | -28.6 | -23.21 | -73.33 | Upgrade
|
| Shares Outstanding (Basic) | 43 | 43 | 10 | 3 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 43 | 43 | 10 | 3 | 3 | Upgrade
|
| Shares Change (YoY) | 0.42% | 314.57% | 222.44% | 11.44% | 58.75% | Upgrade
|
| EPS (Basic) | -0.62 | -0.94 | -2.78 | -7.28 | -25.65 | Upgrade
|
| EPS (Diluted) | -0.62 | -0.94 | -2.78 | -7.28 | -25.65 | Upgrade
|
| Free Cash Flow | -33.12 | -34.09 | -25.34 | -29.2 | -56.37 | Upgrade
|
| Free Cash Flow Per Share | -0.78 | -0.80 | -2.47 | -9.16 | -19.72 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -5219.12% | -8709.98% | -6900.47% | -7189.73% | -4179.48% | Upgrade
|
| Profit Margin | -4646.14% | -7950.90% | -6745.52% | -4865.83% | -7876.37% | Upgrade
|
| Free Cash Flow Margin | -5811.23% | -6804.19% | -5976.65% | -6121.59% | -6054.46% | Upgrade
|
| EBITDA | -29.73 | -43.63 | -29.19 | -34.22 | -38.8 | Upgrade
|
| D&A For EBITDA | 0.02 | 0 | 0.07 | 0.07 | 0.11 | Upgrade
|
| EBIT | -29.75 | -43.64 | -29.26 | -34.3 | -38.91 | Upgrade
|
| Revenue as Reported | 0.57 | 0.5 | 0.42 | 0.48 | 0.93 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.